WallStSmart

Bio Green Med Solution, Inc. (BGMS)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 801080% more annual revenue ($12.22B vs $1.52M). VRTX leads profitability with a 35.5% profit margin vs -204.2%. BGMS trades at a lower P/E of 0.2x. VRTX earns a higher WallStSmart Score of 68/100 (B-).

BGMS

Hold

45

out of 100

Grade: D

Growth: 6.3Profit: 2.0Value: 6.7Quality: 5.8
Piotroski: 4/9Altman Z: -77.25

VRTX

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BGMS.

VRTXUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$952.53

Current Price

$446.83

$505.70 discount

UndervaluedFair: $952.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BGMS3 strengths · Avg: 10.0/10
P/E RatioValuation
0.2x10/10

Attractively priced relative to earnings

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
710.0%10/10

Revenue surging 710.0% year-over-year

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.89B9/10

Large-cap with strong market position

Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

BGMS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.85M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-46.1%2/10

ROE of -46.1% — below average capital efficiency

Free Cash FlowQuality
$-279,0002/10

Negative free cash flow — burning cash

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BGMS

The strongest argument for BGMS centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 710.0% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : BGMS

The primary concerns for BGMS are EPS Growth, Market Cap, Return on Equity.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

BGMS profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

VRTX carries more volatility with a beta of 0.30 — expect wider price swings.

BGMS is growing revenue faster at 710.0% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (68/100 vs 45/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bio Green Med Solution, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. The company is headquartered in Kuala Lumpur, Malaysia.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?